Skip to Content

Arcapta Approval History

  • FDA approved: Yes (First approved July 1st, 2011)
  • Brand name: Arcapta
  • Generic name: indacaterol
  • Dosage form: Neohaler
  • Previous name: QAB149
  • Company: Novartis Pharmaceuticals Corp.
  • Treatment for: COPD

Arcapta (indacaterol inhalation powder) is a long-acting beta2-agonist (LABA) for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).

Development History and FDA Approval Process for Arcapta

Jul  1, 2011Approval FDA Approves Arcapta Neohaler to treat Chronic Obstructive Pulmonary Disease
Mar  9, 2011FDA Advisory Committee Recommends US Approval of Novartis Once-Daily Bronchodilator QAB149 for COPD
Oct 23, 2009Novartis receives Complete Response letter from FDA for QAB149, an investigational bronchodilator for COPD

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.